These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

345 related articles for article (PubMed ID: 29635129)

  • 1. Renal protective effect of SGLT2 inhibitor dapagliflozin alone and in combination with irbesartan in a rat model of diabetic nephropathy.
    Abdel-Wahab AF; Bamagous GA; Al-Harizy RM; ElSawy NA; Shahzad N; Ibrahim IA; Ghamdi SSA
    Biomed Pharmacother; 2018 Jul; 103():59-66. PubMed ID: 29635129
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of Sodium-Glucose Co-Transporter 2 Inhibitor, Dapagliflozin, on Renal Renin-Angiotensin System in an Animal Model of Type 2 Diabetes.
    Shin SJ; Chung S; Kim SJ; Lee EM; Yoo YH; Kim JW; Ahn YB; Kim ES; Moon SD; Kim MJ; Ko SH
    PLoS One; 2016; 11(11):e0165703. PubMed ID: 27802313
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nephropathy in diabetic db/db mice is accelerated by high protein diet and improved by the SGLT2 inhibitor dapagliflozin.
    Nørgaard SA; Briand F; Sand FW; Galsgaard ED; Søndergaard H; Sørensen DB; Sulpice T
    Eur J Pharmacol; 2019 Oct; 860():172537. PubMed ID: 31310751
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of irbesartan on the antioxidant defence system and nitric oxide release in diabetic rat kidney.
    Anjaneyulu M; Chopra K
    Am J Nephrol; 2004; 24(5):488-96. PubMed ID: 15353911
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Does SGLT2 inhibition with dapagliflozin overcome individual therapy resistance to RAAS inhibition?
    Petrykiv S; Laverman GD; de Zeeuw D; Heerspink HJL
    Diabetes Obes Metab; 2018 Jan; 20(1):224-227. PubMed ID: 28685934
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term treatment with the sodium glucose cotransporter 2 inhibitor, dapagliflozin, ameliorates glucose homeostasis and diabetic nephropathy in db/db mice.
    Terami N; Ogawa D; Tachibana H; Hatanaka T; Wada J; Nakatsuka A; Eguchi J; Horiguchi CS; Nishii N; Yamada H; Takei K; Makino H
    PLoS One; 2014; 9(6):e100777. PubMed ID: 24960177
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of sodium glucose cotransporter type 2 inhibitors dapagliflozin on diabetic nephropathy in rats; Inflammation, angiogenesis and apoptosis.
    Elkazzaz SK; Khodeer DM; El Fayoumi HM; Moustafa YM
    Life Sci; 2021 Sep; 280():119018. PubMed ID: 33549594
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dapagliflozin attenuates early markers of diabetic nephropathy in fructose-streptozotocin-induced diabetes in rats.
    Oraby MA; El-Yamany MF; Safar MM; Assaf N; Ghoneim HA
    Biomed Pharmacother; 2019 Jan; 109():910-920. PubMed ID: 30551545
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improved home BP profile with dapagliflozin is associated with amelioration of albuminuria in Japanese patients with diabetic nephropathy: the Yokohama add-on inhibitory efficacy of dapagliflozin on albuminuria in Japanese patients with type 2 diabetes study (Y-AIDA study).
    Kinguchi S; Wakui H; Ito Y; Kondo Y; Azushima K; Osada U; Yamakawa T; Iwamoto T; Yutoh J; Misumi T; Aoki K; Yasuda G; Yoshii T; Yamada T; Ono S; Shibasaki-Kurita T; Hosokawa S; Orime K; Hanaoka M; Sasaki H; Inazumi K; Yamada T; Kobayashi R; Ohki K; Haruhara K; Kobayashi Y; Yamanaka T; Terauchi Y; Tamura K
    Cardiovasc Diabetol; 2019 Aug; 18(1):110. PubMed ID: 31455298
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Renal outcomes with sodium glucose cotransporter 2 (SGLT2) inhibitor, dapagliflozin, in obese insulin-resistant model.
    Jaikumkao K; Pongchaidecha A; Chueakula N; Thongnak L; Wanchai K; Chatsudthipong V; Chattipakorn N; Lungkaphin A
    Biochim Biophys Acta Mol Basis Dis; 2018 Jun; 1864(6 Pt A):2021-2033. PubMed ID: 29572114
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Renal protection by low dose irbesartan in diabetic nephropathy is paralleled by a reduction of inflammation, not of endoplasmic reticulum stress.
    Hartner A; Cordasic N; Klanke B; Menendez-Castro C; Veelken R; Schmieder RE; Hilgers KF
    Biochim Biophys Acta; 2014 Apr; 1842(4):558-65. PubMed ID: 24418215
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of diabetic nephropathy with angiotensin II receptor antagonist.
    Lewis EJ; Lewis JB
    Clin Exp Nephrol; 2003 Mar; 7(1):1-8. PubMed ID: 14586737
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dapagliflozin slows the progression of the renal and liver fibrosis associated with type 2 diabetes.
    Tang L; Wu Y; Tian M; Sjöström CD; Johansson U; Peng XR; Smith DM; Huang Y
    Am J Physiol Endocrinol Metab; 2017 Nov; 313(5):E563-E576. PubMed ID: 28811292
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is Chronic Dialysis the Right Hard Renal End Point To Evaluate Renoprotective Drug Effects?
    Weldegiorgis M; de Zeeuw D; Dwyer JP; Mol P; Heerspink HJL
    Clin J Am Soc Nephrol; 2017 Oct; 12(10):1595-1600. PubMed ID: 28923834
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Empagliflozin, an Inhibitor of Sodium-Glucose Cotransporter 2 Exerts Anti-Inflammatory and Antifibrotic Effects on Experimental Diabetic Nephropathy Partly by Suppressing AGEs-Receptor Axis.
    Ojima A; Matsui T; Nishino Y; Nakamura N; Yamagishi S
    Horm Metab Res; 2015 Aug; 47(9):686-92. PubMed ID: 25611208
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term blockade of angiotensin AT1 receptors increases survival of obese Zucker rats.
    Janiak P; Bidouard JP; Cadrouvele C; Poirier B; Gouraud L; Grataloup Y; Pierre F; Bruneval P; O'Connor SE; Herbert JM
    Eur J Pharmacol; 2006 Mar; 534(1-3):271-9. PubMed ID: 16516882
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Irbesartan ameliorates diabetic nephropathy by reducing the expression of connective tissue growth factor and alpha-smooth-muscle actin in the tubulointerstitium of diabetic rats.
    Ren X; Guan G; Liu G; Liu G
    Pharmacology; 2009; 83(2):80-7. PubMed ID: 19065061
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined SGLT2 and DPP4 Inhibition Reduces the Activation of the Nlrp3/ASC Inflammasome and Attenuates the Development of Diabetic Nephropathy in Mice with Type 2 Diabetes.
    Birnbaum Y; Bajaj M; Yang HC; Ye Y
    Cardiovasc Drugs Ther; 2018 Apr; 32(2):135-145. PubMed ID: 29508169
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Irbesartan type II diabetic nephropathy trial: study design and baseline patient characteristics. For the Collaborative Study Group.
    Rodby RA; Rohde RD; Clarke WR; Hunsicker LG; Anzalone DA; Atkins RC; Ritz E; Lewis EJ
    Nephrol Dial Transplant; 2000 Apr; 15(4):487-97. PubMed ID: 10727543
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of the SGLT-2 inhibitor dapagliflozin on glomerular and tubular injury markers.
    Dekkers CCJ; Petrykiv S; Laverman GD; Cherney DZ; Gansevoort RT; Heerspink HJL
    Diabetes Obes Metab; 2018 Aug; 20(8):1988-1993. PubMed ID: 29573529
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.